David Alden Wood, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 65 Cedar St, Hyannis, MA 02601 Phone: 508-790-0611 Fax: 508-790-0589 |
Dr. Christopher Ryan Jackson, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 65 Cedar St, Hyannis, MA 02601 Phone: 508-790-0611 Fax: 508-790-9754 |
Elizabeth R Mclaughlin, N.P. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 65 Cedar St, Hyannis, MA 02601 Phone: 508-790-0611 Fax: 508-790-0589 |
Ross Alan Johnston, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 65 Cedar St, Hyannis, MA 02601 Phone: 508-790-0611 Fax: 508-790-0589 |
Bruce Roderick Gordon, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 65 Cedar St, Hyannis, MA 02601 Phone: 508-790-0611 Fax: 508-790-0589 |
Edward Farrow Caldwell, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 65 Cedar St, Hyannis, MA 02601 Phone: 508-790-0611 Fax: 508-790-0589 |
Courtney Miller, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 65 Cedar St, Hyannis, MA 02601 Phone: 508-790-0611 |
News Archive
New research reveals that a significant number of adolescents lose their protection from hepatitis B virus (HBV) infection, despite having received a complete vaccination series as infants. Results in the January 2013 issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, suggest teens with high-risk mothers (those positive for HBeAg) and teens whose immune system fails to remember a previous viral exposure (immunological memory) are behind HBV reinfection.
A study led by a neurologist from McGovern Medical School at The University of Texas Health Science Center at Houston showed that a computed tomography could be sufficient for determining thrombectomy treatment in stroke.
Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, announced today the commercial availability of its Stem Cell Colony Purification Application powered by the LEAP™ Cell Processing Workstation.
The answer is yes. Finnish researchers have developed a triumphant solution for predicting responses of breast cancer cells to a set of cancer drugs. The prediction is based on the genomic profiles of the cancer cells. Harnessing genomic profiles of cells in choosing the best treatment is considered the holy grail of personalised medicine.
› Verified 5 days ago